Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IUC8
UPID:
GLT13_HUMAN
Alternative names:
Polypeptide GalNAc transferase 13; Protein-UDP acetylgalactosaminyltransferase 13; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13
Alternative UPACC:
Q8IUC8; Q08ER7; Q68VI8; Q6ZWG1; Q96PX0; Q9UIE5
Background:
Polypeptide N-acetylgalactosaminyltransferase 13, also known as Protein-UDP acetylgalactosaminyltransferase 13 or UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 13, plays a pivotal role in the biosynthesis of O-linked oligosaccharides. It catalyzes the transfer of N-acetyl-D-galactosamine to serine or threonine residues on protein receptors, initiating the synthesis of mucin-type O-glycan core structures and contributing to neurogenesis through glycosylation.
Therapeutic significance:
Understanding the role of Polypeptide N-acetylgalactosaminyltransferase 13 could open doors to potential therapeutic strategies.